Grufity logoGrufity logo

GOSS

1.89USD-0.47(-19.92%)Delayedas of 07 Dec 2022, 10:36 am

Gossamer Bio Inc

Market Summary

USD1.89-0.47Delayedas of 07 Dec 2022, 10:36 am
-19.92%

GOSS Stock Price

RSI Chart

Valuation

Market Cap

990.3M

Price/Earnings

-4.29

Price/Sales

1.6K

Price/Cashflow

-5.36

MarketCap/EBT

-5.17

Price/Sales

Profitability

EBT Margin

-30748.49%

Return on Equity

-765.22%

Return on Assets

-93.87%

Fundamentals

Revenue

Revenue (TTM)

761.0K

Earnings

Earnings (TTM)

-230.8M

Earnings Y/Y

5.63%

Earnings Q/Q

2.28%

Price Action

52 Week Range

1.5915.20
(Low)(High)

Last 7 days

-72.4%

Last 30 days

-77.6%

Last 90 days

-83.9%

Trailing 12 Months

-77.4%

Financial Health

Current Ratio

5.24

Investor Care

Shares Dilution (1Y)

23.63%

Diluted EPS (TTM)

-3.05

Peers (Alternatives to Gossamer Bio)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
6.02% 39.97%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
9.48% 32.58%
24.02
3.61
-1.26% -54.91%
59.1B
21.4B
9.55% -34.59%
4.2
2.57
80.80% 66.61%
41.3B
10.4B
3.42% 30.06%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
-1.32% 48.98%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
7.56% -29.21%
-12.87
32.5
-41.50% -607.58%
3.4B
-
0.89% -37.36%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
-3.53% -59.99%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
30.71% -27.36%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
-
-13.51% -88.17%
-1.22
1.39
9.22% -22.97%
1.6B
69.7M
-4.98% -76.24%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
1.89% -30.47%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-5.25% -58.22%
-4.02
6.06
-17.11% -27.41%
458.1M
10.2M
-10.11% -90.36%
-13.56
44.06
522.71% -141.72%
218.9M
-
-26.53% -81.28%
-2.36
609.63
-71.03% -64.56%

Financials for Gossamer Bio

Income Statement (Last 12 Months)
(In Thousands)
Description(%) Q/Q2021Q42020Q42019Q42018Q4
Revenue-77.9%7613,4425,5631,720
Operating Expenses-216,124
  S&GA Expenses-45,782
Earnings Before Taxes3.8%-233,996.00-243,360.00-180,307.00146,969
Net Income--234,004.00
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-16.6%246295344387433
  Current Assets-17.1%233281332374417
    Cash Equivalents-32.1%94139183213342
  Net PPE-6.7%55566
Liabilities-0.8%262265222217212
  Current Liabilities28.5%4435403630
    LT Debt, Non Current-39.5%1829292929
Shareholder's Equity-75.2%30121170221-
  Retained Earnings-6.6%-917.10-860.60-811.50-755.25-695.00
  Additional Paid-In Capital1.1%901891933925915
Accumulated Depreciation9.7%55443
Shares Outstanding0.2%7777767575
Float-517----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-0.7%-184.85-183.48-188.89-185.12-188.01
  Share Based Compensation5.7%3634323738
Cashflow From Investing45.3%-66.22-120.97-117.43-66.7743
Cashflow From Financing-7.6%33332

Risks

What is the probability of a big loss on GOSS?

95.5%


Probability that Gossamer Bio stock will be more than 20% underwater in next one year

82.6%


Probability that Gossamer Bio stock will be more than 30% underwater in next one year.

61.7%


Probability that Gossamer Bio stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does GOSS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Gossamer Bio was unfortunately bought at previous high price.

Returns

Cumulative Returns on GOSS

-54.9%


3-Year Cumulative Returns

Which funds bought or sold GOSS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
274,000
830,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-3,000
-
-%
2022-11-15
STATE STREET CORP
REDUCED
-2.51
12,824,000
45,259,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
Balyasny Asset Management LLC
NEW
-
560,000
560,000
-%
2022-11-15
Laurel Wealth Advisors LLC
SOLD OFF
-100
-2,000
-
-%
2022-11-15
ALGERT GLOBAL LLC
REDUCED
-12.16
306,000
1,497,000
0.09%
2022-11-15
CreativeOne Wealth, LLC
REDUCED
-20.21
39,000
318,000
0.02%
2022-11-15
ALLIANCEBERNSTEIN L.P.
ADDED
321.63
2,098,000
2,515,000
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
1,272.42
2,621,400
2,762,010
-%

1–10 of 44

Latest Funds Activity

Are funds buying GOSS calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own GOSS

Gossamer Bio News

Marketscreener.com

Goldman Sachs Lowers Price Target on Gossamer Bio to $10 From $22, Maintains Buy Rating.15 minutes ago

Yahoo Finance

GOSS Fair Value

Recent SEC filings of Gossamer Bio

View All Filings
Date Filed Form Type Document
Nov 03, 2022
8-K
Current Report
Nov 03, 2022
10-Q
Quarterly Report
Oct 27, 2022
4/A
Insider Trading
Oct 25, 2022
4
Insider Trading
Oct 25, 2022
4
Insider Trading
Oct 25, 2022
4
Insider Trading

Latest Insider Trading transactions for GOSS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-24
Aranda Richard
SOLD
-57,431.3
12.073
-4,757
Chief Medical Officer
2022-10-24
Carter Laura
SOLD
-58,867.9
12.073
-4,876
Chief Scientific Officer
2022-10-24
Peterson Caryn
SOLD
-57,431.3
12.073
-4,757
EVP, Regulatory Affairs
2022-07-15
Giraudo Bryan
BOUGHT
99,995.5
7.21
13,869
COO/CFO
2022-07-15
Carter Laura
BOUGHT
49,994.1
7.21
6,934
Chief Scientific Officer
2022-07-15
Hasnain Faheem
BOUGHT
999,998
7.21
138,696
President & CEO
2022-07-15
Christian Waage
BOUGHT
49,994.1
7.21
6,934
EVP, Tech Ops and Admin
2022-07-01
Carter Laura
SOLD
-72,648.4
8.248
-8,808
Chief Scientific Officer
2022-06-22
Aranda Richard
SOLD
-12,232.6
6.88
-1,778
Chief Medical Officer

1–10 of 50

Faheem Hasnain
180
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

GOSS Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:    
Research and development$ 44,509$ 43,190$ 129,411$ 129,335
In process research and development15155060
General and administrative11,49712,45934,77535,068
Total operating expenses56,02155,664164,236164,463
Loss from operations(56,021)(55,664)(164,236)(164,463)
Other expense    
Interest income465191989525
Interest expense(3,475)(4,889)(10,423)(14,503)
Other income (expense), net(332)11556721
Total other expense, net(3,342)(4,583)(9,378)(13,257)
Net loss(59,363)(60,247)(173,614)(177,720)
Other comprehensive income (loss):    
Foreign currency translation(173)(64)(319)(274)
Unrealized gain (loss) on marketable securities102(73)(311)(188)
Other comprehensive income (loss)(71)(137)(630)(462)
Comprehensive loss$ (59,434)$ (60,384)$ (174,244)$ (178,182)
Net loss per share, basic (in dollars per share)$ (0.65)$ (0.80)$ (2.14)$ (2.38)
Net loss per share, diluted (in dollars per share)$ (0.65)$ (0.80)$ (2.14)$ (2.38)
Weighted average common shares outstanding, basic (in shares)91,181,42775,001,51081,304,08974,592,632
Weighted average common shares outstanding, diluted (in shares)91,181,42775,001,51081,304,08974,592,632

GOSS Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 153,477$ 183,403
Marketable securities150,906141,815
Restricted cash064
Prepaid expenses and other current assets7,6496,498
Total current assets312,032331,780
Property and equipment, net4,3055,320
Operating lease right-of-use assets6,5725,477
Other assets6291,080
Total assets323,538343,657
Current liabilities  
Accounts payable3633,244
Accrued research and development expenses20,74616,205
Accrued expenses and other current liabilities31,53620,410
Total current liabilities52,64539,859
Long-term convertible senior notes195,496150,038
Debt, non-current portion14,83429,079
Operating lease liabilities - long-term4,2123,218
Total liabilities267,187222,194
Commitments and contingencies (Note 9)
Stockholders' equity  
Common stock, $0.0001 par value; 700,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 94,135,098 shares issued and 93,914,200 shares outstanding as of September 30, 2022, and 76,470,588 shares issued and 75,752,664 shares outstanding as of December 31, 2021108
Additional paid-in capital1,033,385932,944
Accumulated deficit(976,459)(811,534)
Accumulated other comprehensive (loss) income(585)45
Total stockholders' equity56,351121,463
Total liabilities and stockholders' equity$ 323,538$ 343,657